[Heparin and cancer].
The association between cancer and venous thromboembolism is well described. Several studies indicate that elements of the haemostatic system participate in tumour genesis. During the last decade a number of post-hoc analyses of trials not primarily designed to evaluate the effect of low molecular weight heparins (LMWH), on cancer survival, have indicated an increased survival. This has recently been supported by results from several prospective trials with LMWH. The possible anti-cancer effect of LMWH is not known in details. Treatment regimes with LMWH have to be performed.
Lykke
Jakob
J
H:S Bispebjerg Hospital, Kirurgisk Gastroenterologisk Afdeling K, København NV. jly@dadlnet.dk
D000925:Anticoagulants / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D012307:Risk Factors; D015996:Survival Rate; D013923:Thromboembolism / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight